Overview
The marketing authorisation for Lifmior has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.
Lifmior : EPAR - Summary for the public
English (EN)
(667.44 KB - PDF)View
български (BG)
(764.72 KB - PDF)
español (ES)
(666.22 KB - PDF)
čeština (CS)
(743.13 KB - PDF)
dansk (DA)
(664.7 KB - PDF)
Deutsch (DE)
(669.02 KB - PDF)
eesti keel (ET)
(663.42 KB - PDF)
ελληνικά (EL)
(766 KB - PDF)
français (FR)
(667.79 KB - PDF)
hrvatski (HR)
(687.98 KB - PDF)
italiano (IT)
(663.91 KB - PDF)
latviešu valoda (LV)
(741.47 KB - PDF)
lietuvių kalba (LT)
(692.66 KB - PDF)
magyar (HU)
(736.23 KB - PDF)
Malti (MT)
(744 KB - PDF)
Nederlands (NL)
(666.25 KB - PDF)
polski (PL)
(741.21 KB - PDF)
português (PT)
(666.39 KB - PDF)
română (RO)
(690.8 KB - PDF)
slovenčina (SK)
(742.1 KB - PDF)
slovenščina (SL)
(732.49 KB - PDF)
Suomi (FI)
(663.73 KB - PDF)
svenska (SV)
(664.65 KB - PDF)
Product information
Lifmior : EPAR - Product Information
English (EN)
(3.25 MB - PDF)View
български (BG)
(1.91 MB - PDF)
español (ES)
(2.41 MB - PDF)
čeština (CS)
(5.68 MB - PDF)
dansk (DA)
(2.39 MB - PDF)
Deutsch (DE)
(2.62 MB - PDF)
eesti keel (ET)
(2.4 MB - PDF)
ελληνικά (EL)
(7.56 MB - PDF)
français (FR)
(2.48 MB - PDF)
hrvatski (HR)
(2.39 MB - PDF)
íslenska (IS)
(2.46 MB - PDF)
italiano (IT)
(2.48 MB - PDF)
latviešu valoda (LV)
(5.91 MB - PDF)
lietuvių kalba (LT)
(2.49 MB - PDF)
magyar (HU)
(5.66 MB - PDF)
Malti (MT)
(6.04 MB - PDF)
Nederlands (NL)
(2.59 MB - PDF)
norsk (NO)
(2.91 MB - PDF)
polski (PL)
(6.08 MB - PDF)
português (PT)
(2.45 MB - PDF)
română (RO)
(2.51 MB - PDF)
slovenčina (SK)
(5.59 MB - PDF)
slovenščina (SL)
(5.44 MB - PDF)
Suomi (FI)
(2.45 MB - PDF)
svenska (SV)
(3.58 MB - PDF)
Latest procedure affecting product information: IG/1082
05/04/2019
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Lifmior : EPAR - All Authorised presentations
English (EN)
(610.51 KB - PDF)View
български (BG)
(691.52 KB - PDF)
español (ES)
(609.6 KB - PDF)
čeština (CS)
(645.81 KB - PDF)
dansk (DA)
(609.53 KB - PDF)
Deutsch (DE)
(610.23 KB - PDF)
eesti keel (ET)
(606.97 KB - PDF)
ελληνικά (EL)
(653.99 KB - PDF)
français (FR)
(607.67 KB - PDF)
hrvatski (HR)
(608.61 KB - PDF)
íslenska (IS)
(608.15 KB - PDF)
italiano (IT)
(612.85 KB - PDF)
latviešu valoda (LV)
(647.79 KB - PDF)
lietuvių kalba (LT)
(612.9 KB - PDF)
magyar (HU)
(659.6 KB - PDF)
Malti (MT)
(647.64 KB - PDF)
Nederlands (NL)
(608.44 KB - PDF)
norsk (NO)
(608.34 KB - PDF)
polski (PL)
(644.9 KB - PDF)
português (PT)
(612.87 KB - PDF)
română (RO)
(613.7 KB - PDF)
slovenčina (SK)
(644.63 KB - PDF)
slovenščina (SL)
(639.96 KB - PDF)
Suomi (FI)
(606.43 KB - PDF)
svenska (SV)
(613.33 KB - PDF)
Product details
- Name of medicine
- Lifmior
- Active substance
- etanercept
- International non-proprietary name (INN) or common name
- etanercept
- Therapeutic area (MeSH)
- Arthritis, Psoriatic
- Spondylitis, Ankylosing
- Psoriasis
- Anatomical therapeutic chemical (ATC) code
- L04AB01
Pharmacotherapeutic group
ImmunosuppressantsTherapeutic indication
- Rheumatoid arthritis;
- Juvenile idiopathic arthritis
- Psoriatic arthritis;
- Axial spondyloarthritis;
- Plaque psoriasis;
- Paediatric plaque psoriasis.
Assessment history
This page was last updated on